跳至主要内容
临床试验/ISRCTN46080812
ISRCTN46080812已完成不适用

Effectiveness of Hypericum perforatum and Passiflora incarnata extract combination for treatment of depression and accompanied anxiety

Bional Holding BV (The Netherlands)0 个研究点目标入组 150 人开始时间: 2006年7月13日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Male or female patients of eighteen to sixty-five years of age
  • 2. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of mild to moderate (severe) depressive disorder
  • 3. Total severity score of at least 13 and at most 24 at the 17-item Hamilton rating scale for Depression (HAMD) at the entry visit
  • 4. Able to understand the procedures and agreeing to participate by giving written informed consent

排除标准

  • 1. Patients who respond during the first week with a decrease of the total score of the 17-items HAMD of at least 20%
  • Women of child-bearing potential without adequate birth-control measures
  • 3. Women who are pregnant or breast-feeding
  • 4. Treatment with Monoamine Oxidase (MAO) inhibitors during the last two weeks prior to the entry visit
  • 5. Treatment with any psychotropic drug during at least the week preceding the entry visit
  • 6. Contraindication or history of hypersensitivity to the study drugs
  • 7. Unstable and/or severe organ system diseases, e.g. neurological, cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, metabolic, or other
  • 8. History of organ transplantation or Human Immunodeficiency Virus (HIV) positive
  • 9. Usage of immunomodulators, antiretroviral drugs or digoxine
  • 10. Clinical significant abnormalities observed at screening at the discretion of the investigator
  • 11. Substance dependence or abuse according to DSM-IV criteria
  • 12. Bipolar disorder, psychotic features, or any other psychotic disorder
  • 13. Other principal psychiatric diagnosis judged by the investigator to dominate the clinical picture
  • 14. Significant risk for suicide or significant potential for self-harm as judged by the investigator
  • 15. Significant risk for non-compliance with study procedures or drug intake as judged by the investigator

研究者

发起方
Bional Holding BV (The Netherlands)

相似试验